Guardant Health Inc. (GH)
NASDAQ: GHHealth CareMedical SpecialitiesUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
GH stock chart
Technical analysisKey statistics
All statistics- Market cap
- $22.59B
- EPS (TTM)
- -$3.45
- Dividend yield
- None
- 52-week range
- 61.00 – 191.05
- Day range
- 165.00 – 171.55
- Volume / Avg
- 2.20M / 2.01M
- Beta
- —
- Shares outstanding
- 134.20M
- Next earnings
- Nov 4, 2026
52-week range
GH stock today
Shares of Guardant Health (GH) finished lower on Oct 7 at $168.33, a drop of 1.38% or $2.36 per share, versus the S&P 500's 0.22% decline. Shares are 11.9% below their 52-week high of $191.05, set on Oct 6, 2026 and 176.0% above the 52-week low of $61.00, near the top of the past year's range. GH is up 64.8% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 165.3%.
Guardant Health has posted a net loss over the last twelve months (EPS of -$3.45), so its P/E ratio is not meaningful. Guardant Health's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Guardant Health
Company profileGuardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Dr. Helmy Eltoukhy Ph.D.
- Headquarters
- Palo Alto, CA
- Employees
- 2,490
- IPO year
- 2018
- Website
- guardanthealth.com
Financial highlights
Full financialsIn fiscal 2025, Guardant Health generated $982.0 million in revenue, up 32.9% from fiscal 2024, its 8th consecutive year of revenue growth. Guardant Health reported a net loss of $416.3 million, compared with a loss of $436.4 million a year earlier. Gross margin was 64.5% (up from 60.8%) and operating margin -44.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $982.02M | $739.02M | $563.95M | $449.54M | $373.65M |
| Growth | +32.88% | +31.04% | +25.45% | +20.31% | +30.32% |
| Net income | $-416.28M | $-436.37M | $-479.45M | $-654.59M | $-384.77M |
| EPS (diluted) | $-3.32 | $-3.56 | $-4.28 | $-6.41 | $-4.00 |
Analyst forecast
ForecastConsensus (26 analysts)
strong_buy
Avg. price target
$199.84+18.72%
- Strong buy 5
- Buy 20
- Hold 0
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $-0.65
- Last reported (Q2 2026)
- Jul 30, 2026
- EPS actual vs est.
- $-0.90 vs —
Guardant Health peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DGXQuest Diagnostics Incorporated | 227.06 | -0.58% | $25.06B | vs GH |
| LHLabcorp Holdings Inc. | 311.97 | +0.08% | $25.30B | vs GH |
| CNCCentene Corporation | 64.99 | +0.59% | $32.10B | vs GH |
| MOHMolina Healthcare Inc | 194.82 | -0.18% | $10.17B | vs GH |
| OSCROscar Health Inc. Class A | 32.91 | +1.76% | $10.16B | vs GH |
| HSICHenry Schein Inc. | 83.66 | -1.39% | $9.32B | vs GH |
| CAICaris Life Sciences Inc. | 27.10 | -1.29% | $7.66B | vs GH |
| GRALGRAIL Inc. | 132.90 | -3.19% | $5.94B | vs GH |
Indexes, lists and sector
Guardant Health stock FAQ
What is Guardant Health's stock price today?
GH last traded at $168.33 as of Oct 7, 4:00 PM EDT, down 1.38% on the day. Prices are delayed at least 15 minutes.
When is Guardant Health's next earnings date?
Guardant Health is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $-0.65.
Who is Guardant Health's CEO?
Dr. Helmy Eltoukhy Ph.D. is the chief executive officer of Guardant Health Inc., which has about 2,490 employees.
What is the GH 52-week high?
The 52-week high for GH is $191.05 and the 52-week low is $61.00. The stock is currently 11.9% below its high.